Kiora Pharmaceuticals Reports No Revenue and Improved Net Loss in Q3 2025

Kiora Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a significant shift in its financial performance compared to the previous fiscal period. The company recorded no revenue for the three and nine months ended September 30, 2025, a stark contrast to the $16 million in collaboration revenue recognized during the same period in 2024. This decline is attributed to the absence of new collaboration agreements following the substantial upfront payment received from Théa Open Innovation in January 2024. The company’s net loss for the third quarter was $26,806, a notable improvement from a loss of $3.4 million in the prior year, while the nine-month net loss totaled $4.3 million compared to a profit of $7.8 million in 2024.

Kiora's operating expenses for the third quarter decreased significantly to $794,437 from $3.6 million in the same quarter last year, primarily due to the absence of an in-process R&D impairment charge that had impacted the previous year’s results. Research and development expenses increased to $2.7 million, driven by higher preclinical and clinical trial costs, while general and administrative expenses rose slightly to $1.4 million. The company also reported a change in the fair value of contingent consideration, which decreased by $1.7 million, reflecting adjustments in the development plan and discount periods.

In terms of strategic developments, Kiora has made notable progress in its clinical programs. The company is advancing its KIO-301 product, which is currently undergoing a Phase 2 clinical trial for vision restoration in patients with retinitis pigmentosa. Additionally, Kiora entered into an exclusive option agreement with Senju Pharmaceutical Co., Ltd. in May 2025, which could yield up to $110.75 million in potential future payments if the option is exercised. The company is also developing KIO-104 for retinal inflammatory diseases, with patient enrollment for its Phase 2 trial having commenced in the second quarter of 2025.

Kiora's operational metrics indicate a focus on enhancing its research capabilities and expanding its market presence. As of September 30, 2025, the company had cash and cash equivalents of $5.5 million and short-term investments of $13.9 million, providing a total liquidity position that is expected to fund operations into late 2027. The company has also reduced its total liabilities to $7.5 million from $10.7 million at the end of 2024, reflecting a strategic effort to manage its financial obligations effectively.

Looking ahead, Kiora anticipates continued operating losses as it invests in the development of its product candidates. The company acknowledges the need for additional financing to support its operations and plans to pursue various funding avenues, including equity sales, debt financing, and collaboration agreements. While Kiora has historically been successful in raising capital, it cautions that future funding may not be available on favorable terms, which could impact its ability to execute its business strategy.